Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain

Han-Yue Qiu1,2, Xiang Zhu1,2, Yue-Lin Luo1,2, Hong-Yan Lin1,2, Cheng-Yi Tang1,2, Jin-Liang Qi1,2, Yan-Jun Pang3, Rong-Wu Yang2, Gui-Hua Lu1,2, Xiao-Ming Wang1,2 & Yong-Hua Yang1,2

Signal transducer and activator of transcription 3 (STAT3) is hyper-activated in diversiform human tumors and has been validated as an attractive therapeutic target. Current research showed that a natural product, shikonin, along with its synthetic analogues, is able to inhibit the activity of STAT3 potently. The potential space of shikonin in developing novel anti-cancer agents encouraged us to carry out the investigation of the probable binding mode with STAT3. From this foundation, we have designed new types of STAT3 SH2 inhibitors. Combined simulations were performed to filter for the lead compound, which was then substituted, synthesized and evaluated by a variety of bioassays. Among the entities, PMM-172 exhibited the best anti-proliferative activity against MDA-MB-231 cells with IC50 value 1.98 ± 0.49 μM. Besides, it was identified to decrease luciferase activity, induce cell apoptosis and reduce mitochondrial transmembrane potential in MDA-MB-231 cells. Also, PMM-172 inhibited constitutive/inducible STAT3 activation without affecting STAT1 and STAT5 in MDA-MB-231 cells, and had no effect in non-tumorigenic MCF-10A cells. Moreover, PMM-172 suppressed STAT3 nuclear localization and STAT3 downstream target genes expression. Overall, these results indicate that the antitumor activity of PMM-172 is at least partially due to inhibition of STAT3 in breast cancer cells.

The STAT family of proteins is a key mediator transferring extracellular signals into cell nucleus to regulate various cellular processes including proliferation, apoptosis, angiogenesis and other biological activities1, 2. This family consists of seven members which share similarity in structure, albeit they are encoded by disparate genes3. One of the most important family members, the STAT3 protein, is phosphorylated and activated by its upstream kinases such as FAK, JAK and Src4. The phosphorylation of STAT3 leads to the dimerization of its monomers through SH2 domains and after then the STAT3 dimers translocate into cell nucleus to perform their biological functions as gene expression regulator5, 6.

Compelling research shows that aberrantly activated STAT3 is tightly connected with cell dysfunction which causes morbid processes such as tumorigenesis and malignant transformation7. Clinically, the overexpression or constitutively activation of this transcription factor is observed in 70% of human solid and hematological tumors. In turn, inhibiting the activity of STAT3 has proved its potency to hinder the tumor process, both in vitro and in vivo8, 9. Thus STAT3 is considered a promising molecular target in cancer therapies and attracts considerable interest of medicinal chemists10, 11.

Current drug design strategy for suppressing STAT3 activity is mainly comprised of two methods. One is to inhibit its upstream kinases so that the phosphorylation process of STAT3 is thwarted. However, since these kinases target multiple downstream proteins, undesirable adverse effects might appear when other pathways are down-regulated. The other one is to directly suppress the activity of STAT312–14. Compared with the former method, this strategy is more appealing as normal cell functions are minimally disturbed15. To date, a number of STAT3 inhibitors have been identified and being tested in different stages13, 16, 17; still and all, inevitable attrition is predictable during the developing process, and the situation is worse off taking the tumorous inherent tendency of getting resistant and relapsing into consideration. The need of a larger candidate pool applies to almost every therapy strategy of tumor, which is also true for targeting STAT3.

1State Key Laboratory of Pharmaceutical Biotechnology, NJU-NJFU Joint Institute of Plant Molecular Biology, Nanjing University, Nanjing, 210023, China. 2Co-Innovation Center for Sustainable Forestry in Southern China, Nanjing Forestry University, Nanjing, 210037, China. Han-Yue Qiu and Xiang Zhu contributed equally to this work. Correspondence and requests for materials should be addressed to G.-H.L. (email: guihua.lu@nju.edu.cn) or X.-M.W. (email: wangxm07@nju.edu.cn) or Y.-H.Y. (email: yangyh@nju.edu.cn)
Recent research showed that shikonin (SHK), the main efficacy component of the Chinese herbal medicine *Lithospermum erythrorhizon*, is capable to block the STAT3 pathway. Especially in breast cancer models, SHK exhibited impressive pharmacological characters which are related with its effect on STAT3. Besides, recent reports have revealed that many synthetic STAT3 inhibitors, such as plumbagin and LLL-12, share the same backbone with SHK, hinting a scaffold bias for the target STAT3. Hence SHK might be a good starting point for modification to achieve new agents with improved profile against STAT3 and relating tumors.

In this work we primarily explored the potential binding mode of SHK with STAT3. On the basis we employed Scaffold Growth strategy to furnish a library of modifications, which were then selected by virtual screen. Molecular dynamics simulation was also performed to validate the docking results. The outcome showed that the optimization provided several entities with improved potency compared with their scaffold SHK.

**Results**

**Chemistry.** The synthesis of compounds PMM-158–PMM-173 followed the general pathway outlined in Fig. 1B. All synthesized compounds were reported and characterized for the first time, and gave satisfactory analytical and spectroscopic data. The 1H NMR and ESI-MS spectra were in full accordance with the assigned structures (shown in the Supplementary Information).

**Molecular docking and scaffold modification.** The homodimerization of STAT3 is mediated by the PPI (protein-protein interaction) between SH2 domains of each STAT3 monomers, and the pTyr705 plays a vital role in this process. In the SH2 domains of STAT3, three adjacent binding subpockets were explored as the binding hot spots, namely pY-X (Δ 592–605), pY + 0 (591, Δ 609–620), and pY + 1 (Δ 626–639) site. The site pY + 0 binds with pTyr705 and contains polar residues responsible for hydrogen bonding and electrostatic interactions, and the other two subpockets pY + 1 and pY-X are formed by hydrophobic residues. Most of the known STAT3 inhibitors targeting the SH2 domain targeting at least two of these three subpockets. In this work, docking simulations were performed iteratively. We primarily explored the binding mode of SHK with STAT3, as shown in Fig. 2A and Fig. 2B, the starting SHK mainly located in the pY-X and pY + 0 subpockets. Docking screening was employed to rank these candidates. In addition to the virtual screening, the synthetic accessibility for these candidates was taken into consideration. At last, the lead compound illustrated in Fig. 1A was validated. It was then substituted to furnish a class of derivatives which were also tested by docking simulation. The docking results are summarized in Table 1, the lead compound occupied the same two subpockets pY-X and pY + 0 assembling its scaffold SHK.
Besides, it interacts with the same residues LYS 591, GLU 594 and ILE 634 comparing with SHK (Fig. 2C,D), however one more hydrogen bonds with residue ARG595 was formed, along with the coming up of additional interactions induced by the modification part.

**MD trajectory analysis.** In this study, we analyzed the dynamic behavior in the ligand-binding site of the STAT3-inhibitor complexes. It's well established that the root mean square deviation (RMSD) fluctuation is an important criterion to gauge whether the protein-ligand system was stable. During the process of MD simulation, the maximum RMSD for each system was limited to 0.3 nm (Fig. 2E). The RMSDs of all the systems gradually became stable after 1 ns, indicating that they reached equilibrium. It has been shown that PMM-172 became stable quickly and could present an equilibrium state for more than 3 ns. Notably, we found that the RMSD of

---

**Figure 2.** Binding mode of SHK and lead compound PMM-158 with STAT3 (PDB code: 1BG1). (A) 2D diagram of the interaction between SHK and amino acid residues of the nearby active site. (B) 3D diagram of SHK inserted in the STAT3 binding site: for clarity, 3D structure of the protein is presented in line ribbon and only interacting residues are displayed. (C) 2D diagram of the interaction between PMM-158 and amino acid residues of the nearby active site. (D) 3D diagram of PMM-158 inserted in the STAT3 binding site: for clarity, 3D structure of the protein is presented in line ribbon and only interacting residues are displayed. (E) The RMSDs of the three studied complexes obtained during 5 ns of MD simulations, SHK (blue), lead compound (red) and PMM-172 (black).
PMM-172 remains stable throughout the whole process of simulation, suggesting its distinct comparative advantage against other compounds.

**PMM-172 inhibited cell growth and STAT3 transcriptional activity.** Initial experiments were performed for evaluation of growth inhibition by the new compounds against six human breast cancer cell lines, including MCF-7 (ER+/PR+, HER-2-), BT474 (ER+/PR+, HER-2+), SKBR-3 (ER-/PR-/HER-2+), MDA-MB-436 (ER-/PR-/HER-2-), MDA-MB-231 (ER-/PR-/HER-2-), MDA-MB-468 (ER-/PR-/HER-2-) and non-tumorigenic MCF-10A cells. After 24 h treatment by the obtained compounds, the inhibition was assessed and the IC_{50} was summarized. The results shown in Table 1 indicated that all compounds had lower toxicity against the non-tumorigenic MCF-10A cells than SHK itself. As shown in Table 2, the new synthetic compounds showed high sensitivity to three triple negative cells and HER2 over-expression cells than to the other two subtypes. Fortunately, we obtained some compounds with strong cytotoxicity toward human breast cancer cells while avoiding non-tumorigenic MCF-10A cells. Among them, PMM-172 (IC_{50} = 1.98 ± 0.49 μM) showed better anti-proliferative activity against MDA-MB-231 cells than SHK (IC_{50} = 2.88 ± 0.25 μM). Subsequently, the inhibition of STAT3 activation by PMM-172 and Stattic was evaluated using a dual-luciferase assay. The results (Fig. 3) suggested that PMM-172 decreased the STAT3 luciferase activity in a dose-dependent manner, while the effects of Stattic showed only a slight advantage over PMM-172.

**PMM-172 induced apoptosis in MDA-MB-231 cells in dose- and time-dependent manners.** To determine whether PMM-172 induced apoptosis, Annexin V/PI double staining assay was conducted. MDA-MB-231 cells were treated with various concentrations of PMM-172 for 24 h, and the percentage of apoptotic cells was markedly elevated in a dose-dependent manner. Likewise, MDA-MB-231 cells were treated with

| Compd   | R          | Interaction energy ΔG_0 (kcal/mol) | CC_{50} (μM) MCF-10A |
|---------|------------|-----------------------------------|----------------------|
| PMM-158 |            | −56.6335                          | 92.5 ± 0.27          |
| PMM-159 |            | −55.7343                          | 89.5 ± 0.99          |
| PMM-160 |            | −57.7694                          | 68.3 ± 0.27          |
| PMM-161 |            | −59.1773                          | 84.5 ± 0.74          |
| PMM-162 |            | −59.4741                          | 91.9 ± 1.21          |
| PMM-163 |            | −61.1946                          | 86.2 ± 0.33          |
| PMM-164 |            | −59.9377                          | 74.6 ± 0.55          |
| PMM-165 |            | −61.361                           | 83.7 ± 1.28          |
| PMM-166 |            | −56.5488                          | 69.9 ± 0.58          |
| PMM-167 |            | −59.8725                          | 72.5 ± 1.53          |
| PMM-168 |            | −60.3577                          | 80.6 ± 1.07          |
| PMM-169 |            | −60.9084                          | 99.5 ± 0.49          |
| PMM-170 |            | −61.8761                          | 94.6 ± 0.83          |
| PMM-171 |            | −62.6852                          | 76.2 ± 1.15          |
| PMM-172 |            | −63.1153                          | 95.4 ± 0.62          |
| PMM-173 |            | −59.983                           | 88.9 ± 0.34          |
| Shikonin|            | −59.4517                          | 23.5 ± 1.01          |

Table 1. The interaction energy and anti-proliferative activity against non-tumorigenic MCF-10A cells of the target compounds.
further assess the pro-apoptotic effect of PMM-172, we evaluated the cleavage of poly (ADP-ribose) polymerase. The results indicated that longer treatment periods showed an increasing tendency in the percentage of apoptotic cells. To conclusion that PMM-172 induced apparent apoptosis in MDA-MB-231 cells in dose- and time-dependent manners. The PARP involved in DNA repair and programmed cell death is considered as the hallmark of apoptosis. The results of western blot showed that PMM-172 could induce PARP and caspase 3 cleavage in MDA-MB-231 cells in a dose-dependent, which were in accordance with the above results (Fig. 4E). Taken together, we obtained the con-

| Compound | IC₅₀ (µM) | MCF-7 | BT-474 | SKBR-3 | MDA-MB-436 | MDA-MB-231 | MDA-MB-468 |
|----------|-----------|-------|--------|--------|------------|------------|------------|
| PMM-158  | 12.1 ± 0.42 | 15.6 ± 1.03 | 11.5 ± 0.74 | 10.1 ± 0.92 | 9.17 ± 0.99 | 10.6 ± 0.65 |
| PMM-159  | 9.22 ± 0.13 | 10.8 ± 0.94 | 8.95 ± 0.69 | 8.49 ± 0.78 | 7.24 ± 0.82 | 8.23 ± 1.27 |
| PMM-160  | 15.3 ± 0.52 | 18.3 ± 1.24 | 10.5 ± 0.88 | 11.8 ± 0.86 | 9.66 ± 1.21 | 12.4 ± 0.52 |
| PMM-161  | 9.81 ± 0.49 | 11.1 ± 1.12 | 9.29 ± 0.66 | 9.55 ± 0.83 | 8.58 ± 0.53 | 8.97 ± 1.05 |
| PMM-162  | 9.01 ± 0.92 | 9.54 ± 0.91 | 8.03 ± 0.83 | 7.28 ± 0.77 | 6.14 ± 1.05 | 6.85 ± 0.92 |
| PMM-163  | 8.69 ± 0.83 | 9.27 ± 0.86 | 7.56 ± 0.72 | 7.09 ± 0.63 | 6.04 ± 0.59 | 7.83 ± 0.55 |
| PMM-164  | 5.71 ± 0.52 | 7.09 ± 0.65 | 4.49 ± 0.58 | 4.41 ± 0.55 | 3.76 ± 1.02 | 3.94 ± 0.73 |
| PMM-165  | 9.38 ± 0.66 | 9.22 ± 0.98 | 6.23 ± 0.73 | 5.97 ± 0.67 | 5.47 ± 1.01 | 6.58 ± 0.15 |
| PMM-166  | 6.41 ± 0.75 | 6.91 ± 0.73 | 4.87 ± 0.58 | 4.66 ± 0.59 | 3.64 ± 0.91 | 4.07 ± 0.66 |
| PMM-167  | 15.3 ± 0.61 | 13.7 ± 0.92 | 9.76 ± 0.95 | 10.6 ± 0.82 | 9.91 ± 0.56 | 12.2 ± 0.42 |
| PMM-168  | 9.27 ± 1.12 | 10.6 ± 0.81 | 8.16 ± 0.71 | 7.87 ± 0.91 | 6.09 ± 1.04 | 8.42 ± 0.86 |
| PMM-169  | 8.12 ± 0.98 | 8.36 ± 0.97 | 6.95 ± 0.82 | 7.36 ± 0.87 | 5.33 ± 0.77 | 7.22 ± 1.11 |
| PMM-170  | 9.73 ± 1.03 | 12.7 ± 1.06 | 8.27 ± 0.69 | 6.88 ± 0.73 | 4.31 ± 0.65 | 8.44 ± 0.78 |
| PMM-171  | 8.71 ± 0.67 | 8.59 ± 0.78 | 5.89 ± 0.64 | 6.49 ± 0.68 | 3.14 ± 1.02 | 6.95 ± 0.46 |
| PMM-172  | 4.87 ± 0.55 | 5.26 ± 0.66 | 3.14 ± 0.46 | 3.07 ± 0.47 | 1.98 ± 0.49 | 3.24 ± 0.27 |
| PMM-173  | 5.58 ± 0.83 | 6.03 ± 0.71 | 3.59 ± 0.49 | 4.06 ± 0.53 | 2.59 ± 0.19 | 3.76 ± 0.88 |
| Shikonin  | 4.57 ± 0.69 | 5.74 ± 0.66 | 3.75 ± 0.52 | 3.28 ± 0.41 | 2.88 ± 0.25 | 3.61 ± 0.34 |
| Stattic   | 5.85 ± 0.72 | 5.11 ± 0.57 | 3.39 ± 0.56 | 3.76 ± 0.50 | 3.18 ± 0.33 | 3.54 ± 0.42 |

Table 2. Anti-proliferative activity against six kinds of breast cancer cells by all compounds.

Figure 3. MDA-MB-231 cells were transfected with STAT3-TATA-Luc reporter and Renilla luciferase reporter plasmids. After 24 h, cells were treated with indicated concentrations of PMM-172 or Stattic for 24 h and then luciferase intensity was measured. Results are fold change ± SD of three independent experiments, *P < 0.05, **P < 0.01.

corresponding doses of Stattic. As shown in Fig. 4A, increased apoptotic rate was detected after cells being treated with escalating concentrations of PMM-172. The percentages of cell apoptosis 3.12%, 8.12%, 16.81%, 62.74% corresponded to the concentration of PMM-172 0, 2, 4 and 8 µM, respectively, including both the early and the late apoptotic cells. Clearly, PMM-172 can cause cell apoptosis more effectively than Stattic. Moreover, an extend time-course apoptosis analysis of MDA-MB-231 cells treated with 4 µM PMM-172 was carry out. The results indicated that longer treatment periods showed an increasing tendency in the percentage of apoptotic cells. To further assess the pro-apoptotic effect of PMM-172, we evaluated the cleavage of poly (ADP-ribose) polymerase (PARP) and caspase 3 in MDA-MB-231 cells after 24 h treatment with PMM-172. In this case, the active form of PARP involved in DNA repair and programmed cell death is considered as the hallmark of apoptosis. The results of western blot showed that PMM-172 could induce PARP and caspase 3 cleavage in MDA-MB-231 cells in a dose-dependent, which were in accordance with the above results (Fig. 4E). Taken together, we obtained the conclusion that PMM-172 induced apparent apoptosis in MDA-MB-231 cells in dose- and time-dependent manners.

PMM-172 reduced mitochondrial transmembrane potential in MDA-MB-231 cells. Subsequently, the mitochondrial transmembrane potential was monitored using JC-1 staining. The Fig. 5 shows representative JC-1 fluorescence in both FL-1 and FL-2 channels. Red fluorescence represents the mitochondrial aggregate
Figure 4. The effect of PMM-172 on the cell apoptosis of MDA-MB-231 cells. (A) MDA-MB-231 cells were treated with various concentrations of PMM-172 or Stattic for 24 h, or treated with 4 μM PMM-172 for different time. Apoptosis was analyzed by flow cytometry by using Annexin V/PI double staining. (B) The percentage of apoptotic cells in MDA-MB-231 cells treated with various concentrations of PMM-172 for 24 h. (C) The percentage of apoptotic cells in MDA-MB-231 cells treated with 4 μM PMM-172 for different time. (D) The percentage of apoptotic cells in MDA-MB-231 cells treated with various concentrations of Stattic for 24 h. (E) PARP and caspase 3 cleavage in MDA-MB-231 cells after treated with various concentrations of PMM-172 for 24 h were detected by using Western blot analysis. The relative expression level was analyzed by Image J software. Data were shown as mean ± SD of three independent experiments. *P < 0.05, **P < 0.01. Cropped blots/gels were used in the figure and the gels had been run under the same experimental conditions; the full-length blots/gels are presented in Supplementary Figure S1.
form of JC-1 with high $\Delta \Psi_m$ in normal cells. Green fluorescence represents the monomeric form of JC-1 with low $\Delta \Psi_m$ in apoptotic cells. However, cells treated with PMM-172 exhibited increased green fluorescence and decreased red fluorescence, suggesting the depolarization of mitochondria and reduced $\Delta \Psi_m$. The ratio of cells with high membrane potential exposed to 4 $\mu$M and 8 $\mu$M PMM-172 decreased from 92.3% to 64.6% and 21.3% after 4h treatment.

**PMM-172 reduced constitutive and inducible STAT3 activation in MDA-MB-231 cells.** It has been well recognized that the aberrant activation of STAT3 contributes to malignant transformation and tumorigenesis, and its activity is ultimately dependent upon phosphorylation of residue Y705. Hence the Y705-phosphorylated level of STAT3 is an important metric to evaluate the inhibitory efficacy of STAT3 antagonists. In this study, the ability of PMM-172 and Stattic inhibiting the constitutive STAT3 activation in MDA-MB-231 cells was investigated. Western blot analysis (Fig. 6A and D) revealed that PMM-172 and Stattic could reduce the level of Y705-phosphorylated STAT3 in MDA-MB-231 cells in a dose-dependent manner, and had no effect on STAT3 expression. By comparison, we found that the inhibitory effect of PMM-172 was more potent than Stattic. We further measured STAT3 phosphorylation at Tyr705 in a time-course experiment. As shown in Fig. 6B and E, the phosphorylation of residue Tyr705 in STAT3 is reduced with the longer treatment of PMM-172 or Stattic.

We further investigated whether PMM-172 could inhibit IL-6-induced STAT3 phosphorylation in MDA-MB-231 cells. As shown in Fig. 6C, IL-6 stimulation on MDA-MB-231 cells increased the levels of phosphor-STAT3 while the pretreatment of PMM-172 suppressed IL-6-induced STAT3 phosphorylation without affecting STAT3 expression.

Subsequently, we evaluated the phosphorylation level of other STAT family proteins including STAT1 and STAT5. The results (Fig. 6F) showed PMM-172 inhibited neither the phosphorylation nor expression of STAT1 and STAT5, indicating that the inhibition of STAT3 activation by PMM-172 may be specific.

**PMM-172 suppressed STAT3 nuclear localization.** It is known that the dimerization of STAT3 is induced by the phosphorylation at residue Tyr 705, which then leads to its nuclear translocation. Herein, we investigated the effect of PMM-172 and Stattic on STAT3 nuclear translocation. The cytoplasmic and nuclear proteins of treated cells were extracted and the expressions of STAT3 in both fractions were examined. The results (Fig. 7A) showed that the level of STAT3 in the nuclear fraction was decreased by PMM-172 in a dose-dependent manner, while the level of STAT3 was slightly increased in the cytoplasmic fraction. As shown in Fig. 7B, the effect of PMM-172 to suppress STAT3 nuclear localization showed a slight advantage over Stattic.

**PMM-172 does not suppress STAT3 activation nor viability in normal cells.** In the following work, we examined whether PMM-172 could affect the activity of STAT3 and viability in non-cancer cells. The non-tumorigenic MCF-10A epithelial cells were employed to be treated with increasing doses of PMM-172 to conduct this assay. It is noteworthy that PMM-172 had no effect on the level of the pSTAT3 level in MCF-10A cells, and the expression levels of total STAT3 kept unchanged (Fig. 7C). The cell viability was evaluated using MTT assay, and the results revealed that the growth of MCF-10A cells was barely inhibited by PMM-172 (Table 1). Taken together, these results indicated that PMM-172 primarily suppressed STAT3 activation and viability in STAT3-dependent breast cancer cells.
PMM-172 inhibited STAT3 downstream target genes expression. STAT3 target genes are vital to the dysfunctional biology processes induced by the aberrantly activated STAT3. Therefore, we investigated whether PMM-172 suppresses the expression of STAT3-regulated genes related to cell survival, proliferation and apoptosis in MDA-MB-231 cells. As shown in Fig. 7D, the treatment with PMM-172 for 24 h down-regulated the expression of Bcl-2, Bcl-xL, survivin and cyclin D1 in a dose-dependent manner.

Discussion
The research advance on the biological information of STAT3 has paved the way for its utilization in cancer therapy. Also, current efforts on exploiting STAT3-targeting agents have made impressive progress: an increasing number of synthetic and natural-occurring chemical entities have been reported with potent STAT3 inhibition efficiency since the last decade. Yet remarkable challenges are foreseeable transferring the testing agents into clinical drugs. Apart from the attrition in the preclinical and clinical studies, the developing of a certain chemotype into approved medicine is also likely to be plagued by resistance and relapse of tumor. In this situation, an ample multiformity in chemical space is favorable to explore for different kinds of inhibitors which shall alleviate the coming problems. Of note is that the traditional Chinese herbals provide a non-negligible candidate pool for digging of new STAT3 inhibitors. Diverse in structure, these natural products brought new understanding in the biological functional mechanism with STAT3 and novel starting points with considerable improving space31–35. Attempts in the characterization and optimization for these NP as STAT3 inhibitors may yield admirable outputs. Also noteworthy is that some NPs are restricted in medicinal use not only for the complexity of purification or/
and synthesis, but also for the difficulty in optimization. As one of the most famous medicinal plant metabolites, SHK is unlike some other “untamed” NPs for bearing sites apt to be modified in structure. Based on the knowledge that SHK has a remarkable STAT3 inhibitory profile, it’s of interest to investigate its probable molecular mechanism and explore for optimizations.

In this study, the binding mode of SHK with STAT3 was primarily explored by virtual simulation with a high ranking score. On the basis of maintaining key intermolecular interactions with receptor STAT3, we applied the scaffold growth strategy to modify the backbone SHK and establish a small library of SHK derivatives with higher binding affinity. Iterative docking screen simulations were performed to rank all the new compounds and the top hit was validated. The hit compound PMM-158 shared a quite similar binding modality with its original scaffold SHK, while the substituent group provided additional favorable interactions. Structural modification was carried out to PMM-158 in order to gain a further understanding on the structure-activity relationship. Also, molecular

**Figure 7.** MDA-MB-231 cells were treated with indicated concentrations of PMM-172 or Stattic for 24 h, the expression levels of STAT3 in cytoplasmic and nuclear extracts were examined and relative expression levels were analyzed by Image J software. β-actin and Lamin B1 served as markers of cytoplasmic and nuclear extractions, respectively. (A) PMM-172 suppressed STAT3 nuclear localization. (B) Stattic suppressed STAT3 nuclear localization. (C) MCF-10A cells were treated with the indicated concentrations of PMM-172 for 24 h. PMM-172 had no effect on the level of the pSTAT3 level in MCF-10A cells. (D) PMM-172 down-regulated the expression of STAT3 target genes. Data were shown as mean ± SD from three independent experiments, **P < 0.01. Cropped blots/gels were used in the figure and the gels had been run under the same experimental conditions; the full-length blots/gels are presented in Supplementary Figure S3.
dynamics was performed to the complex systems of SHK, PMM-158 and PMM-172 with protein STAT3 to detect their robustness. The fluctuant RMSD values for both systems and ligands were quite stable in the equilibrium state, hinting a high reliability of the binding models.

After the systematic synergetic simulation work, the target compounds were synthesized and tested in vitro to depict their pharmacological profile. According to Table 1, the obtained synthetics had lower toxicity against the non-tumorigenic MCF-10A cells than SHK. Also these compounds exerted more potent anti-proliferative activity against HER2 over-expression cell line and triple negative cell lines than the other two cell lines (shown in Table 2). Among all the entities, PMM-172 showed better anti-proliferative activity against one triple negative cell line MDA-MB-231 (IC_{50} = 1.98 ± 0.49 μM) than SHK (3.28 ± 0.41 μM) and Stattic (3.76 ± 0.50 μM). What's more, PMM-172 could decrease the STAT3 luciferase activity in a dose-dependent manner, and the effect was similar with Stattic.

Subsequently, we investigated the effects of PMM-172 on cell apoptosis in MDA-MB-231 cells. The results demonstrated that PMM-172 induced cell apoptosis in dose- and time-dependent manners, and more effectively than Stattic. Also the elevated expression of cleaved PARP and cleaved caspase-3, which are hallmark of cell apoptosis, were observed by the treatment with increased concentration of PMM-172. Furthermore, the depolarization of mitochondria and reduced mitochondrial transmembrane potential by PMM-172 were confirmed. Taken together, these results indicated that PMM-172 induced the cell apoptosis of MDA-MB-231 cells through the mitochondrial pathway.

For the mechanistic study, we found that PMM-172 inhibited the constitutive/inducible STAT3 activation in MDA-MB-231 cells, and showed a slight advantage over Stattic. In contrary, the level of the phosphorylated STAT3 was not affected by PMM-172 in non-cancer MCF-10A cells. The expression levels of STAT1, STAT5 and their phosphorylated forms in MDA-MB-231 cells were further detected to character the selectivity of PMM-172. While no obvious changes were observed in the phosphorylation levels of STAT1 and STAT5, a conclusion may be safely conducted that PMM-172 primarily suppressed STAT3 activation in STAT3-dependent breast cancer cells.

It has been reported that the suppression of STAT3 activation results in the reduction of nuclear localization of STAT3. When exerting PMM-172 on MDA-MB-231 cells, the expression levels of STAT3 in nuclear fractions were reduced, in accordance with the mentioned reports. Also it’s known that after phosphorylation, STAT3 translocates into the nuclear where it binds to a specific promoter to regulate targeted genes expression related to cell survival, proliferation and apoptosis. In our study, levels of representative downstream proteins including Bcl-2, Bcl-XL, survivin and cyclin D1 were measured to reveal that PMM-172 could down-regulate the expression of STAT3 target genes in MDA-MB-231 cells.

Collectively, these results favored our design intention and hinted this type of natural product derivatives might be helpful in the further explorations of potent STAT3 inhibitors.

Methods
Materials and measurements. All chemicals (reagent grade) were used purchased from Nanjing Chemical Reagent Co. Ltd. (Nanjing, China). All the 1H NMR spectra were recorded on a Bruker DPX 300 model Spectrometer in CDCl3 and chemical shifts (δ) were reported as parts per million (ppm). ESI-MS spectra were recorded a Mariner System 5304 Mass spectrometer. Elemental analyses were performed on a CHNO-Rapid instrument and were within 0.4% of the theoretical values. Thin layer chromatography (TLC) was performed on silica gel plates (Silica Gel 60 GF254) and visualized in UV light (254 nm). Column chromatography was performed using silica gel (200–300 mesh) eluting with ethyl acetate and petroleum ether (bp. 30–60 °C).

STAT3 Antibody (#12640), phospho-STAT3 (Tyr705) Antibody (#9131) and GAPDH Antibody (#2118) were purchased from Cell Signaling Technology (Beverly, MA). BCL-XL Antibody (WLA0558), Bcl-2 Antibody (WLA1556), Survivin Antibody (WLA1684), Cyclin D1 Antibody (WLA1435a), β-actin Antibody (WLA10774), Lamin B Antibody (WLA0175), and Goat anti-rabbit IgG (H + L) (WLA023a) were purchased from Wanleibio Co., Ltd. (Shenyang, China). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) were purchased from Sigma-Aldrich (St. Louis, USA). Annexin V-FITC Apoptosis Detection Kit (A211-01/02) was purchased from Vazyme Biotech Co., Ltd (Nanjing, China).

Docking simulation and scaffold modification. The STAT3 crystal structure (PDB code: 1BG1) was deposited from the PDB database as a dimer. Afterwards, the missing residues in STAT3 (residues 185–193, 689–701, and 717–722) were added using Modeller. The target was prepared using Accelrys Discovery Studio version 3.5. Following the protocol, the hydroxyl at the branching chain of SHK was marked as site to be substituted. To increase the diversity, all the reaction types provided by the software were selected. After calculation, modified molecules were produced and combined with molecules designed empirically to furnish a library of small molecules. We used CDocker of Discovery Studio 3.5 to dock the pre-generated conformations into STAT3 and small-molecule compounds with high scores were selected to further confirm their pharmacological activities.

Molecular dynamics (MD) simulations. To further verify the binding model, MD simulations were carried out using the GROMACS package (version 5.1.2). Proteins were charged using the GROMOS96 43a1p force field (which could handle with pTyr residue) and the small molecules were prepared using PRODRG. The
complex was solvated in a dodecahedron water box (1-nm thick) of SPC water molecules and periodic boundary conditions were applied in all directions. Periodic boundary conditions (PBC) were employed to avoid edge effects in MD simulations. The systems were neutralized with Na\(^+\) and Cl\(^-\) counter ions and the long-range electrostatic interactions were calculated by the particle mesh Ewald method. Prior to performing the MD simulation, energy minimization was carried out to clear poor contacts. Then, 100 ps NVT and 100 ps NPT ensembles with simultaneous protein–ligand position restraints were also carried out to equilibrate the system. Consequently, 10 ns MD production simulation was performed with a 2 fs time step at constant temperature (300 K) and pressure (1 atm).

**General procedure for the synthesis of compounds PMM-158–PMM-173.** Shikonin, C1–C16, 4-dimethylaminopyridine (DMAP) and N, N'-dicyclohexyl-carbodiimide (DCC) were dissolved in dichloromethane. The reaction was stirred at ice bath for 8 h and monitored by TLC. After the completion of the reaction, the product PMM-158–PMM-173 was obtained and purified by column chromatography.

**Cell Culture.** Human breast cancer cells and human non-tumorigenic breast cells (MCF-10A) were purchased from Nanjing Keygen Technology (Nanjing, China). Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Hyclone) (High Glucose) with L-glutamine supplemented with 10% fetal bovine serum (FBS, BI), 100 U/mL penicillin and 100 mg/mL streptomycin (Hyclone), and incubated at 37 °C in a humidified atmosphere containing 5% CO\(_2\).

**Anti-proliferation assay.** The anti-proliferative activities of the prepared compounds against MCF-7 (ER+/PR+, HER-2-), BT474 (ER+/PR+, HER-2+), SKBR-3 (ER+/PR+/HER-2+), MDA-MB-436 (ER+/PR-/HER-2-), MDA-MB-231 (ER-/PR-/HER-2-), MDA-MB-468 (ER-/PR-/HER-2-) and non-tumorigenic MCF-10A cell lines were evaluated using a standard (MTT)-based colorimetric assay with some modification. Cell lines were grown to log phase in DMEM supplemented with 10% fetal bovine serum. Cell suspensions were prepared and 100 μL/well dispensed into 96-well plates giving 10⁴ cells/well. The subsequent incubation was permitted at 37 °C, 5% CO\(_2\) atmosphere for 24 h to allow the cells to reattach. Subsequently, cells were treated with the target compounds at increasing concentrations in the presence of 10% FBS for 24 h. Then, cell viability was assessed by the conventional 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction assay and carried out strictly according to the manufacturer instructions. The absorbance (OD₅₇₀) was read on an ELISA reader (Tecan, Austria). In all experiments, three replicate wells were used for each drug concentration. Each assay was carried out for at least three times.

**Luciferase assay.** Cells were seeded in 24 well plates and transiently transfected together with STAT3 reporter plasmid 4× M67 pTATA TK-Luc (0.2 μg/well, Addgene, USA) and Renilla luciferase control reporter plasmid pRL-CMV (0.1 μg/well, promega, USA), using lipofectamine 2000 (Invitrogen, USA). Then the cells were incubated with complete medium for 24 h with PMM-172 or Stattock. Following the treatment, the cells were harvested in 100 μL of passive lysis buffer (Promega, USA) in each well. A 25 μL aliquot of cell lysate was subjected to a luciferase assay by using the dual-luciferase assay kit (Promega, USA). STAT3 luciferase activity was measured by EnVision Multilabel Reader (Perkin Elmer, USA). Relative luciferase activity was calculated after the activity of STAT3-dependent firefly luciferase had been normalized to that of Renilla luciferase. All values are expressed as - fold induction relative to basal activity.

**Cell apoptosis assay.** Approximately 10⁵ cells/well were plated in a 24 well plate and allowed to adhere. Subsequently, the medium was replaced with fresh culture medium containing PMM-172 or Stattock. Non-treated wells received an equivalent volume of ethanol (≤0.1%). After 24 h, they were trypsinized, washed in PBS and centrifuged at 2000 rpm for 5 min. The pellet was then resuspended in 500 μL of staining solution (containing 5 μL Annexin V-FITC and 5 μL PI in Binding Buffer), mixed gently and incubated for 15 min at room temperature in dark. The samples were then analyzed by a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA).

**Mitochondrial membrane potential evaluation.** Mitochondrial transmembrane potential (ΔΨm) was detected using a JC-1 mitochondrial membrane potential assay kit (Beyotime Biotech), following the manufacturer’s protocol. After the treatment, the cells were incubated at 37 °C for 20 min with 5 μg/mL JC-1 (5,5,6,6-tetrachloro-1,1,3,3-tetraethylbenzimidazolylcarbocyanine iodide), then washed twice with PBS and incubated in fresh medium without serum. The samples were analyzed using a FACSCalibur cytometer (Becton Dickinson) equipped with a 488 nm argon laser.

**Preparation of cytoplasmic and nuclear extracts.** To examine the relative proportion of STAT3 in the nucleus and cytoplasmic and nuclear extracts were prepared. In brief, control and treated cells were collected and suspended in a buffer containing 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA (pH 8.0), 0.1 mM EGTA (pH 7.0), 1 mM DTT, 0.5 mM PMSE, 2 μg/mL leupeptin, 2 μg/mL aprotinin, 0.5 mg/mL benzamidine. After 15 min, NP-40 (0.25%) was added, and cell lysate was vortexed for 10 s and centrifuged at 10000 rpm at 4 °C for 1 min. The supernatants were transferred to fresh tubes and considered as cytoplasmic extract. The pellets were resuspended in a buffer containing 20 mM HEPES (pH 7.9), 400 mM NaCl, 1 mM EDTA (pH 8.0), 1 mM EGTA (pH 7.0), 1 mM DTT, 1 mM PMSE, 2 μg/mL leupeptin, 2 μg/mL aprotinin, 0.5 mg/mL benzamidine. After 30 min incubation on ice, the extract was centrifuged at 14000 rpm at 4 °C for 10 min, and the resultant
supernatants were collected as nuclear extracts. The protein content in the nuclear and cytoplasmic fractions was determined using a Pierce BCA protein assay kit.

**Western blot analysis.** Cells were rinsed twice with cold PBS and then lysed with RIPA buffer containing a protease inhibitor mixture at 1:100 dilution on ice for 30 min. Insoluble components of cell lysates were removed by centrifugation (4 °C, 12,000 rpm, 10 min), and protein concentrations were measured using a Pierce BCA protein assay kit. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred from the gel onto polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% skim milk in TBST buffer for 1 h at room temperature, and then incubated with corresponding primary antibodies diluted in 5% milk-TBST solution at 4 °C with gentle shaking overnight. After washing five times (5 min each), corresponding HRP-conjugated secondary antibodies were incubated for 1 h at room temperature. Immunoreactive bands were visualized using an ECL detection kit (Invitrogen, USA) following the manufacturer's instruction.

**IL-6 induction of STAT3 phosphorylation.** Cells were seeded in 10 cm plates and allowed to adhere over-night. The following day, the specimen was serum starved for 24 h. The specimen was then treated with or without tested agents at the dose of 2 μM. After 24 h, the treated specimen was stimulated with IL-6 (25 ng/mL). Cells were then harvested after 30 min and analyzed by Western blot.

**Statistical analysis.** All data are expressed as mean ± SD. The statistical analysis was performed by the Student’s t-test, using the statistical software OriginPro 2015. P values < 0.05 were considered statistically significant.

**References**
1. Lai, F. S. et al. A STAT inhibitor patent review: progress since 2011. Expert opinion on therapeutic patents 25, 1397–1421 (2015).
2. Mukkossy, G., Hilliard, T. S. & Turkson, J. Therapeutic modulators of STAT signalling for human diseases. Nature reviews drug discovery 12, 611–629 (2013).
3. Furtak, S. L., Backos, D. S., Matheson, C. J. & Reigan, P. Strategies and Approaches of Targeting STAT3 for Cancer Treatment. ACS chemical biology 11, 388–318 (2016).
4. Bharadwaj, U. et al. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene 34, 1341–1353 (2015).
5. Zhang, X. et al. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochemical pharmacology 79, 1398–1409 (2010).
6. Matsuno, K. et al. Identification of a New Series of STAT3 Inhibitors by Virtual Screening. ACS medicinal chemistry letters 1, 371–375 (2010).
7. Sandur, S. K., Pandey, M. K., Sung, B. & Aggarwal, B. B. 5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization. Molecular cancer research: MCR 8, 107–118 (2010).
8. Nguyen, A. V. et al. STAT3 in Epithelial Cells Regulates Inflammation and Tumor Progression to Malignant State in Colon. Neoplasia 15, 998–1008 (2013).
9. Sanchez-Lopez, E. et al. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. Oncogene 35, 2634–2644 (2016).
10. Siven, K. S. et al. Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochimica et Biophysica Acta (BBA) - reviews on cancer 1845, 136–154 (2014).
11. Emeghi, P. U. et al. Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy. Gene Therapy 20, 1085–1092 (2013).
12. Huang, W. et al. A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion. ACS chemical biology 9, 1188–1196 (2014).
13. Li, H. et al. Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying calecebox and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3). Journal of medicinal chemistry 54, 5592–5596 (2011).
14. Yu, W., Xiao, H., Lin, J. & Li, C. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design. Journal of medicinal chemistry 56, 4402–4412 (2013).
15. Siddiquie, K. et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proceedings of the national academy of sciences of the United States of America 104, 7391–7396 (2007).
16. Cafferkey, C. & Chau, I. Novel STAT3 inhibitors for treating gastric cancer. Expert opinion on investigational drugs 25, 1023–1031 (2016).
17. Lai, P. S. et al. A STAT inhibitor patent review: progress since 2011. Expert opinion on therapeutic patents 25, 1397–1421 (2015).
18. Xu, Y., Xu, X., Gao, X., Chen, H. & Geng, L. Shikonin suppresses IL-17-induced VEGF expression via blockade of JAK2/STAT3 pathway. International immunopharmacology 19, 327–333 (2014).
19. Andujar, I., Ross, J. L., Giner, R. M. & Recio, M. C. Pharmacological properties of shikonin - a review of literature since 2002. Planta medica 79, 1685–1697 (2013).
20. Liu, L. et al. Shikonin inhibits IFN-γ-induced K17 over-expression of HaCaT cells by interfering with STAT3 signaling. International journal of clinical and experimental pathology 8, 9202–9207 (2015).
21. Thakur, R., Trivedi, R., Rastogi, N., Singh, M. & Mishra, D. P. Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Scientific reports 5, 10194 (2015).
22. Fuh, B. et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. British journal of cancer 100, 106–112 (2009).
23. Yan, W. et al. Suppressive effects of plumagin on invasion and migration of breast cancer cells via the inhibition of STAT3 signaling and down-regulation of inflammatory cytokine expressions. Bone research 1, 362–370 (2013).
24. Xiao, H. et al. A novel small molecular STAT3 inhibitor, LYS, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells. The journal of biological chemistry 290, 3418–3429 (2015).
25. Lin, L. et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer research 71, 7226–7237 (2011).
26. Yao, Y. & Zhou, Q. A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells. Breast Cancer Research and Treatment 121, 233–240 (2010).
27. Zhang, Y., Qian, R.-Q. & Li, P.-P. Shikonin, an ingredient of Lithospermum erythrorhizon, down-regulates the expression of steroid sulfatase genes in breast cancer cells. Cancer Letters 294, 47–54 (2009).
28. Chen, Y. et al. Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways. *International Immunopharmacology* **21**, 447–455 (2014).
29. Wang, Y. et al. Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway. *Biochemical pharmacology* **88**, 322–333 (2014).
30. Qiu, H. Y. et al. Synthesis of dihydropropazole sulphonamide derivatives that act as anti-cancer agents through COX-2 inhibition. *Pharmaceutical research* **104**, 86–96 (2016).
31. Boykin, C. et al. Cucurbitacin Ila: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation. *British journal of cancer* **104**, 781–789 (2011).
32. Choi, B. Y. & Kim, B. W. Withaferin-A Inhibits Colon Cancer Cell Growth by Blocking STAT3 Transcriptional Activity. *Journal of cancer prevention* **20**, 185–192 (2015).
33. Dai, F., Gao, L., Zhao, Y., Wang, C. & Xie, S. Farrerol inhibited angiogenesis through Akt/mTOR, Erk and Jak2/Stat3 signal pathway. *Phytomedicine: international journal of phytotherapy and phytopharmacology* **23**, 686–693 (2016).
34. Baek, S. H. et al. Resveratrol inhibits STAT3 signaling pathway through the induction of SOCS-1: Role in apoptosis induction and radiosensitization in head and neck tumor cells. *Phytomedicine: international journal of phytotherapy and phytopharmacology* **23**, 566–577 (2016).
35. Rahman, N., Jeon, M., Song, H. Y. & Kim, Y. S. Cryptotanshinone, a compound of Salvia miltiorrhiza inhibits pre-adipocytes differentiation by regulation of adipogenesis-related genes expression via STAT3 signaling. *Phytomedicine: international journal of phytotherapy and phytopharmacology* **23**, 58–67 (2016).
36. Lin, J. et al. Molecular dynamics simulations of the conformational changes in signal transducers and activators of transcription, Stat1 and Stat3. *Journal of molecular graphics & modellling* **28**, 347–356 (2009).
37. Jung, S. N. et al. Sugiol inhibits STAT3 activity via regulation of transketolase and ROS-mediated ERK activation in DU145 prostate carcinoma cells. *Biochemical pharmacology* **97**, 38–50 (2015).
38. Cheng, M. H. & Coalson, R. D. Molecular Dynamics Investigation of Cl– and Water Transport through a Eukaryotic CLC Transporter. *Biophysical Journal* **102**, 1363 (2012).

**Acknowledgements**
The authors are grateful to the Program for Changjiang Scholars and Innovative Research Team in University (IRT_14R27), the National Natural Science Foundation of China (NSFC) (Nos 31470384, 31171161, 31670298), and the fund for University Ph.D. Program from the Ministry of Education of China (20120091110037).

**Author Contributions**
H.Q., X.Z., X.W. and Y.Y. designed the experiments and wrote the main manuscript. Y.L., H.L., and C.T. performed the experiments in cell line. J.Q., Y.P. , R.Y. and G.L. collected and analyzed the data. All authors reviewed the manuscript.

**Additional Information**
Supplementary information accompanies this paper at doi:10.1038/s41598-017-02671-7

**Competing Interests:**
The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2017